Sigyn Therapeutics (OTCMKTS:SIGY) vs. SI-BONE (NASDAQ:SIBN) Critical Analysis

Sigyn Therapeutics (OTCMKTS:SIGY) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk and Volatility

Sigyn Therapeutics has a beta of -1.58, meaning that its stock price is 258% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sigyn Therapeutics and SI-BONE’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$2.93 million	($0.09)	-3.56
SI-BONE	$106.41 million	8.23	-$61.26 million	($1.35)	-16.77

Sigyn Therapeutics has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Sigyn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sigyn Therapeutics and SI-BONE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-850.32%
SI-BONE	-38.32%	-40.35%	-27.29%

Analyst Ratings

This is a summary of current ratings and target prices for Sigyn Therapeutics and SI-BONE, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	N/A
SI-BONE	0	0	7	0	3.00

SI-BONE has a consensus price target of $28.00, indicating a potential upside of 23.67%. Given SI-BONE’s higher probable upside, analysts clearly believe SI-BONE is more favorable than Sigyn Therapeutics.

Summary

SI-BONE beats Sigyn Therapeutics on 5 of the 9 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc. operates as a medical technology company, focuses on creating therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. It also developing ChemoPrep to enhance the tumor site delivery of chemotherapy; and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. The company is headquartered in San Diego, California.

About SI-BONE

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.